Key result
The Micra TPS leadless pacemaker achieved a 97.8% implantation success rate, but was associated with a 9.8% major complication rate over an average 1-year follow-up.
Why the study?
What is the real-world clinical safety and efficacy of the Micra TPS leadless pacemaker in patients requiring single-chamber pacing?
Observational (n=92)
Yes
What is the real-world clinical safety and efficacy of the Micra TPS leadless pacemaker in patients requiring single-chamber pacing?
While real-world implantation of the Micra TPS leadless pacemaker has a high success rate, it is associated with a high major complication rate (9.8%) during initial experience, highlighting the need for proper training.
Answers are grounded in this paper and cite their sources.
Real-world Swiss Micra data support safety and efficacy; leaves open need for larger prospective confirmation of long-term outcomes.
AIMS: Leadless pacemakers are implanted in Switzerland since June 2015. Large worldwide registries have shown high implant success, low complication rates, and good electrical parameters up to 12 months' follow-up. However, data are scarce outside the investigational setting. The purpose of this study is to assess the real-world experience regarding clinical safety and efficacy of Micra TPS (transcatheter pacing system) leadless pacemakers. METHODS AND RESULTS: Retrospective observational, multi-centre study designed to assess initial safety and efficacy of the Micra TPS in the Swiss Romande region. A total of 92 patients were included from four different centres with an implantation success rate of 97.8% (90 of 92). Thresholds were overall low at implantation (median 0.38 V/0.24 ms, ranging from 0.13 to 2.88 V/0.24 ms) and remained stable over 1-year follow-up. The perioperative serious adverse event rate was 6.5% in six patients which lead to prolonged hospitalization in five patients and death in one patient. In addition, three further major events (3.3%) occurred during an average follow-up of 1 year, requiring implantation of a standard transvenous pacemaker in two patients, and surgical explantation of the Micra TPS in one patient due to intractable ventricular tachycardia. CONCLUSION: Leadless pacemakers are a valuable adjunct for treating selected patients requiring single-chamber pacing. However, in this initial experience, major complication rates were high (9.8%). The implant procedure requires proper training and should be performed in an adequate setting.
No takes yet. Share an insight, caveat, or question.
Valiton et al. (2018) conducted an observational in Patients requiring single-chamber pacing (n=92). Micra TPS leadless pacemaker was evaluated on major complication rate. The Micra TPS leadless pacemaker achieved a 97.8% implantation success rate, but was associated with a 9.8% major complication rate over an average 1-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: